News | October 17, 2007

Cordis to Present Data Supporting Cypher at TCT 2007

October 18, 2007 - Cordis Corp. will present clinical data backing the CYPHER Sirolimus-eluting coronary stent at the annual Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007), which will take place in Washington, D.C. from October 20-25. Data from several studies will highlight the CYPHER Sirolimus-eluting Coronary Stent, as well as other products from the company’s peripheral vascular group.

“The studies that will be presented at this year's meeting will continue to add to the significant body of scientific evidence for the CYPHER Stent and our diverse portfolio of current and future products, which range from a carotid artery stent system to a wound closure device," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "The studies and presentations will further validate the clinical advantages of drug-eluting stents compared with bare metal stents, highlight economic data of stenting versus surgery, and feature the clinical benefits of the CYPHER Stent versus the Taxus Stent."

The schedule of key Cordis-related events includes:


3:15 p.m. Eastern Time (ET)

Carotid Workshop - Pooled Analysis of Three Carotid Artery Stenting Trials

Room 202A

Barry T. Katzen, M.D. of the Baptist Cardiac and Vascular Institute in Miami, Florida will present a pooled analysis of three carotid artery stenting trials to assess 30-day major adverse events rates, comprising death, all stroke and/or heart attack (myocardial infarction), in high-risk patients based on anatomic versus physiological risk factors. The analysis was pooled from the pivotal SAPPHIRE randomized and registry stent cohorts and the CASES-PMS study, which involved the PRECISE Stent and ANGIOGUARD Emboli Capture Guidewire.

No previous analysis has been reported regarding whether patients undergoing carotid artery stenting with emboli protection, who are at high-risk for carotid endarterectomy, have a higher risk for major adverse events based on anatomic versus co-existing physiological risk factors prior to carotid stenting. Additional analysis assessing one-year outcomes of these subgroups will also be presented.

3:32 p.m. ET

Oral Presentation - ECLIPSE Trial

Room 202B

S. Chiu Wong, M.D. of New York-Presbyterian Hospital/Weill Cornell Medical Center will present perspectives on extravascular sealing devices and a first report of the ECLIPSE Trial, a multicenter, non-blinded, randomized study designed to measure the safety and efficacy of the EXOSEAL(TM) Vascular Closure Device versus manual compression to close vascular access sites in patients having undergone diagnostic or interventional procedures.

The EXOSEAL(TM) Vascular Closure Device features a synthetic bioabsorbable polymer and is being studied to determine whether it can enable expedited hemostasis (the cessation of bleeding), faster patient ambulation (ability to walk) and reduced bed-stay after a catheterization procedure. Nearly eight million patients undergo cardiac catheterization procedures annually.


12:51 p.m. ET

Oral Presentation - ACROSS and PRISON II Trials

Ballroom C, Level 3

Dr. Kandzari will present six-month data results of the ACROSS Registry and PRISON II randomized clinical trial designed to evaluate the CYPHER Stent used in patients with chronic total occlusions.


7:00 p.m. ET

Symposium - "New Evidence in DES Outcomes: The Road Traveled Since the World Congress of cardiology 2006"

Grand Hyatt Constitution Ballroom

A panel of distinguished speakers that includes Christian M. Spaulding, M.D., PhD of Cochin Hospital in France; Stephan Windecker, M.D. of Swiss Cardiovascular Center Bern in Switzerland; Jeffrey W. Moses, M.D., of Columbia University Medical Center in New York; and Lowell F. Satler, M.D. of Washington Hospital Center will discuss the drug-eluting stent landscape and how to apply current evidence to clinical practice. Topics of discussion will include the impact of media headlines on clinical practice, the latest data set on percutaneous coronary interventions, applying the evidence of drug-eluting stents to clinical practice and the future of sirolimus-eluting stents.


9:09 a.m. Eastern Time

Oral Presentation - "Temporal Trends in Coronary Revascularization Procedures, Outcomes and Costs: Results From the U.S. Medicare Program"

Room 151AB

Jason W. Ryan, M.D., M.P.H. of Beth Israel Deaconess Medical Center in Boston, Massachusetts will present a comparison of pre-drug-eluting stent implantation in 2001 to post-drug-eluting stent implantation in 2004; Dr. Ryan will provide an update on temporal trends, outcomes and costs from this time period associated with coronary revascularization procedures, including percutaneous interventions and bypass surgery, from the Medicare program in the United States.


1:45 p.m. ET

Oral Presentation - ARTS II

Coronary Theatre - Lower Level

Bernard De Bruyne, M.D., Ph.D. of Cardiovascular Center, OLV Hospital, Aalst, Belgium will present two-year data results from the ARTS-II Trial, which compared the safety and efficacy of the CYPHER Stent versus BMS and CABG. Dr. Bruyne will present data from the study assessing the impact of gender following multivessel drug-eluting stent implantation.


Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init